Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

I also expect '113 will be best in class. However, with six others in waiting, it will not be easy, and it will take time. The fact that Ariad is now going after a new mutation target that no one else has targeted, speaks volumes and means Ariad is maturing and shifting their approach. If they started out with that focus, Ariad could have been big. The days of treating patients who have failed another drug, meaning the patients are already weak, are over, I hope. Look at the response rate for '113 with naive ALK+ patients. It was 100%. There are many new targets for many cancer indications that could be explored. If Ariad only had a start-over-button..